iCAD (NASDAQ:ICAD – Get Free Report) issued its quarterly earnings data on Wednesday. The technology company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02, Zacks reports. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%.
iCAD Price Performance
ICAD traded up $0.15 during trading on Wednesday, hitting $2.47. The company had a trading volume of 386,180 shares, compared to its average volume of 248,226. iCAD has a 1-year low of $1.18 and a 1-year high of $3.78. The company has a market cap of $65.55 million, a PE ratio of -19.00 and a beta of 1.95. The business has a 50-day moving average of $2.63 and a 200-day moving average of $2.05.
Analyst Upgrades and Downgrades
Separately, StockNews.com lowered shares of iCAD from a “hold” rating to a “sell” rating in a report on Tuesday.
About iCAD
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
See Also
- Five stocks we like better than iCAD
- Do ETFs Pay Dividends? What You Need to Know
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Using the MarketBeat Stock Split Calculator
- Alphabet’s Officially In A Bear Market—Time To Buy?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
